SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (112)	6/29/2000 6:56:00 AM
From: Jim Oravetz	Read Replies (1) of 164

CALGARY-(BW)-June 28, 2000-Oncolytics Biotech Inc. (TSE:ONC.)(CDNX:ONC.) today reported that Dr. Ron Moore and his research group at the Cross Cancer Institute in Edmonton, Alberta presented the results of their work with REOLYSIN used to selectively kill superficial transitional cell carcinoma (TCC) of the bladder in animal models. The results were presented today at the Annual Meeting of the Canadian Urological Association. The purpose of the investigation was to compare the efficacy of REOLYSIN to standard interventions of this disease state. Animal survival, tumor response, and potential side effects were all examined. The results of investigation demonstrated better efficacy with fewer adverse outcomes for animals receiving REOLYSIN as compared to the standard treatment. In an animal model of TCC, Dr. Moore's group found that 70% of the animals had no evidence of tumours after treatment with REOLYSIN, with no evidence of toxicology found as a result of treatment. "Between 50-70% of human TCCs have the abnormality that would make them susceptible to REOLYSIN therapy," said Dr. Moore. "It is exciting that REOLYSIN can be placed in the bladder and selectively eliminate cancer cells." The full abstract of the presentation can be found on Oncolytics' web site. Oncolytics is a biotechnology company whose focus is the development of the reovirus known as REOLYSIN as a potential cancer therapeutic. The human reovirus infects and kills cancer cells with an activated Ras pathway. Ras is an important component of a pathway controlling normal growth and differentiation of a cell and when activated, may account for a large proportion of all human tumours. Researchers believe that targeting this pathway could have broad potential in the treatment of many cancers. Oncolytics researchers demonstrated that REOLYSIN was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic, and brain tumours, as well as being able to treat tumours successfully in a number of animal models. Oncolytics initiated a Phase I clinical trial on REOLYSIN in June of 2000. 40%(?) owned by SYBBF Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next